Natco Pharma Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/eoehlzh5xpr6h0q41ffowbj7.pdf

Key Takeaways


The Revlimid Cliff: Managing the Transition

Rajeev Nannapaneni: "I think the challenge that we face in our business is that we are not consistent. I mean we'll have 3, 4 good years and we'll have 2 years of dip, and again then we'll have to 3 good years again but I think that's the nature of the risk that we take."

Pipeline: A Portfolio of Asymmetric Bets

Rajeev Nannapaneni: "We never think in terms of near term. we always think about long term. And I think all our ideas are 5 years, 7 years, 8 years away. But I think when they come big."

Financial Performance & Margin Outlook

Rajeev Nannapaneni: "if you don't have a big product, then you can't spend on R&D also, so then the expenses also get reduced by that much. I mean you can't say that I'll spend like a lot of money, but I don't have a profit. You only spend if you make the money. Both are interlinked, right?"

Domestic & Emerging Markets: Waiting for a Catalyst

Rajeev Nannapaneni: "Without pipeline, you have nothing. And you need to have pipeline where you're backward integrated doing your own manufacturing, only then you have margin. Otherwise, there is no margin also."

Strategy & Business Model Conviction

Rajeev Nannapaneni: "So even if you're able to pull off 6 or 7 ideas in the next 8 to 10 years, I think you have done a great job."

Guidance & Commitments

CommitmentSpecificsTimeline
PAT growth20% growth over last year; management says they have been conservative and should do betterFY25
Margin sustainabilityMaintain current margin profile (~60%) for this year and next yearFY25 and FY26
December quarterWill be weaker than Q2; some tail left from volume adjustmentQ3 FY25
Crop protection breakevenBusiness expected to break evenStarting March 2026
Revlimid market shareExpect to capture one-third of total marketBy January
Revlimid clarityMore clarity on next year's performancePost-December results / post-March earnings
Semaglutide India launchRegulatory approval and launch expected post-compound expiryPost-2026, by FY27
Domestic business growthExpect business to compound at 15-20% over a 2-3 year perspective, driven by Semaglutide2-3 year perspective
Olaparib litigationTrial date set1-1.5 years from now

Key Metrics

MetricQ2 FY25
Consolidated total revenue₹1,434.9 cr, growth of 35.3% YoY vs ₹1,060.8 cr
Consolidated net profit₹676.5 cr, growth of about 82% YoY vs ₹369 cr
Operating margin60%, expected to be maintained this year and next year
R&D spend (bio-studies and exhibit batches)₹100–125 cr in the quarter
Second interim dividend₹1.5 per equity share declared for FY25
FY25 PAT growth guidance20% growth over last year, management indicated conservative and may do better
Subsidiaries top line₹120 cr contributed by all subsidiaries combined
Domestic formulation business outlookExpected to compound at 15–20% over 2–3 years
Crop protection business annual loss₹40–50 cr per year, targeting breakeven by March '26
Semaglutide patent expiry timelinePatents expiring in '31, '33, and '35
Olaparib economics50-50 profit share with Alembic
Tabrecta (capmatinib) market size$11–12 million product, sole FTF with 100% economics retained
Potential cash by FY26$400–500 million
Acquisition transaction range under evaluation$3 million to $300 million range